基本信息
浏览量:18
职业迁徙
个人简介
He sat on the Board of Nabriva Therapeutics and was instrumental in that company's initial funding and IPO. He was a co-founder of AN2 Therapeutics, where he currently serves as Senior Advisor; AN2 recently completed a successful listing on NASDAQ. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), previously sat on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. He has co-authored more than 110 publications in peer-reviewed scientific journals.
研究兴趣
论文共 2 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
George H Talbot,Anita Das, Stephanie Cush,Aaron Dane,Michele Wible,Roger Echols,Antoni Torres,Sue Cammarata,John H Rex,John H Powers,Thomas Fleming, Jeffrey Loutit,
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn